Yervoy

0:01:53

İpilimumab İmmunoterapi Prof Dr Başak Oyan Uluç

0:01:33

CHECKMATE 920: nivolumab plus ipilimumab for renal cell cancer

0:23:27

Immunotherapy with High Dose Interleukin 2: Role in the Era of Yervoy and Zelboraf

0:02:48

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

0:02:01

Nivolumab, Ipilimumab in Metastatic Colorectal Cancer

0:01:49

COSMIC-313: cabozantinib with nivolumab and ipilimumab in untreated aRCC

0:00:57

Ipilimumab plus nivolumab with sacituzumab govitecan in mUC

0:02:00

Nivolumab and Ipilimumab in mRCC

0:07:03

Ipilimumab/Nivolumab for Favorable-Risk mRCC

0:02:34

KEYNOTE-029: pembrolizumab with ipilimumab for melanoma

0:06:13

CheckMate-227: Testing Ipilimumab/Nivolumab in NSCLC

0:03:17

Nivolumab With Ipilimumab for Small Cell Lung Cancer

0:04:17

Prix Galien USA 2012 / Best Biotechnology Product: Yervoy® - Bristol-Myers Squibb

0:02:09

Dr. Apolo on Cabozantinib Plus Nivolumab and Ipilimumab in Urothelial Carcinoma

0:01:05

Nivolumab and Ipilimumab Combination in Frontline mCRC

0:01:24

Dr. McDermott on Nivolumab Plus Ipilimumab in RCC

0:00:47

Dr. Wolchok on Weighing Risk and Benefit of Nivolumab/Ipilimumab Combo in Melanoma

0:06:03

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

0:03:24

Ipilimumab Side Effect Management in Melanoma

0:05:19

I-O Therapy in mCRC: Ipilimumab + Nivolumab

0:00:56

Everything About Yervoy (Ipilimumab) - Immunotherapy for Cancer

0:07:13

Progression patterns in post-ipilimumab and anti-PD-1 in metastatic melanoma

0:05:57

Adjuvant Ipilimumab in High-Risk Melanoma

0:01:24

Dr. Atkins on Adjuvant Ipilimumab in Melanoma